AR117164A1 - Derivados de amino-triazoloquinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso para el tratamiento de diversos tipos de cáncer - Google Patents
Derivados de amino-triazoloquinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso para el tratamiento de diversos tipos de cáncerInfo
- Publication number
- AR117164A1 AR117164A1 ARP190103450A ARP190103450A AR117164A1 AR 117164 A1 AR117164 A1 AR 117164A1 AR P190103450 A ARP190103450 A AR P190103450A AR P190103450 A ARP190103450 A AR P190103450A AR 117164 A1 AR117164 A1 AR 117164A1
- Authority
- AR
- Argentina
- Prior art keywords
- 6alkyl
- substituted
- 4alkyl
- derivatives
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Derivados de 5-amino-[1,2,4]triazolo[1,5-c]quinazolina como inhibidores de al menos uno de los receptores de adenosina A2a y A2b; composiciones farmacéuticas que los comprenden y el uso de los mismos solos o en combinación con otros agentes terapéuticos para el tratamiento de diversos tipos de cáncer incluyendo cáncer de próstata metastásico. Reivindicacion1: Un compuesto que tiene una fórmula estructural (1), o una sal de aquel farmacéuticamente aceptable, en donde: R¹ se selecciona de F, Cl, C₁₋₆alquilo y OC₁₋₆alquilo; R² se selecciona de H, F, Cl, C₁₋₆alquilo y OC₁₋₆alquilo; el anillo A es una porción seleccionada de: los compuestos del grupo de fórmulas (2); R³ se selecciona de pirazolilo, triazolilo y piridinilo, en donde dicho pirazolilo y dicho triazolilo se sustituyen con 1 ó 2 grupos R³A, y en donde dicho piridinilo se sustituye con 1, 2 ó 3 grupos R³A, en donde: cada R³A se selecciona independientemente de C₁₋₆alquilo, OC₁₋₆alquilo, C₁₋₆alquil-OH, C₁₋₆haloalquilo, OC₁₋₆haloalquilo, oxo, C₁₋₄alquilC(O)C₁₋₃alquilo, C₁₋₄alquilCH(OH)C₁₋₃alquilo, C₁₋₄alquilS(O)₂C₁₋₃alquilo, -(CH₂)ₙC₃₋₇cicloalquilo y -(CH₂)ₙheterocicloalquilo monocíclico de 4 - 7 miembros que comprende 1 ó 2 heteroátomos del anillo seleccionados de oxígeno y nitrógeno, en donde C₃₋₇cicloalquilo y heterocicloalquilo monocíclico de 4 - 7 miembros son cada uno no sustituidos o sustituidos con 1, 2 ó 3 grupos seleccionados independientemente de F, Cl, OH, C₁₋₆alquilo y C₁₋₆haloalquilo; n es 0, 1 ó 2; RA¹ se selecciona de H y C₁₋₄alquilo; RA² se selecciona de H, F y C₁₋₄alquilo; RA³ se selecciona de H, F y C₁₋₄alquilo; RA⁴ se selecciona de H y OH; y RA⁵ se selecciona de H, F y C₁₋₄alquilo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862774077P | 2018-11-30 | 2018-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR117164A1 true AR117164A1 (es) | 2021-07-14 |
Family
ID=69005832
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190103450A AR117164A1 (es) | 2018-11-30 | 2019-11-26 | Derivados de amino-triazoloquinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso para el tratamiento de diversos tipos de cáncer |
Country Status (25)
Country | Link |
---|---|
US (2) | US11312719B2 (es) |
EP (1) | EP3886988A1 (es) |
JP (1) | JP7241871B2 (es) |
KR (1) | KR102653800B1 (es) |
CN (1) | CN113329791A (es) |
AR (1) | AR117164A1 (es) |
AU (1) | AU2019385905B2 (es) |
BR (1) | BR112021010427B1 (es) |
CA (1) | CA3120862C (es) |
CL (1) | CL2021001406A1 (es) |
CO (1) | CO2021006888A2 (es) |
CR (1) | CR20210271A (es) |
DO (1) | DOP2021000104A (es) |
EA (1) | EA202191498A1 (es) |
EC (1) | ECSP21036982A (es) |
IL (1) | IL283334A (es) |
JO (2) | JOP20210116A1 (es) |
MA (1) | MA54298A (es) |
MX (1) | MX2021006329A (es) |
NI (1) | NI202100043A (es) |
PE (1) | PE20211768A1 (es) |
PH (1) | PH12021551196A1 (es) |
SG (1) | SG11202105180PA (es) |
TW (1) | TW202039496A (es) |
WO (1) | WO2020112700A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS53072B (en) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | HUMAN RECEPTOR ANTIBODIES PROGRAMMED DEATH PD-1 |
US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
CN109475531B (zh) | 2016-05-31 | 2021-08-17 | 得克萨斯州立大学董事会 | Ptpn11的杂环抑制剂 |
MX2020011528A (es) | 2018-05-02 | 2021-02-09 | Navire Pharma Inc | Inhibidores heterociclicos sustituidos de ptpn11. |
EP4356973A3 (en) | 2018-08-10 | 2024-06-26 | Navire Pharma, Inc. | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer |
WO2023158626A1 (en) * | 2022-02-16 | 2023-08-24 | Merck Sharp & Dohme Llc | Adenosine receptor antagonists, pharmaceutical compositions and their use thereof |
WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2109577A1 (de) | 1971-03-01 | 1972-09-14 | Boehringer Mannheim Gmbh | Antimikrobiell wirksame Nitrofuran Derivate und Verfahren zur Herstellung derselben |
US3957766A (en) | 1970-06-19 | 1976-05-18 | Boehringer Mannheim G.M.B.H. | Novel nitrofuran compounds and pharmaceutical compositions |
US4713383A (en) | 1984-10-01 | 1987-12-15 | Ciba-Geigy Corporation | Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses |
GB9524395D0 (en) | 1995-11-29 | 1996-01-31 | Nickerson Biocem Ltd | Promoters |
US6759759B2 (en) | 2000-08-29 | 2004-07-06 | Tamagawa Seiki Kabushiki Kaisha | Rotary contactless connector and non-rotary contactless connector |
KR100687954B1 (ko) | 2001-10-15 | 2007-02-27 | 쉐링 코포레이션 | 아데노신 A2a 수용체 길항제로서의이미다조(4,3-e)-1,2,4-트리아졸로(1,5-c) 피리미딘 |
AR038366A1 (es) | 2001-11-30 | 2005-01-12 | Schering Corp | Compuestos de 1,2,4-triazolo [1,5-c] pirimidinas sustituidas, antagonistas del receptor de adenosina a2a, composiciones farmaceuticas, el uso de dichos compuestos para la manufactura de un medicamento para el tratamiento de enfermedades del sistema nervioso central y un kit que comprende combinacion |
EP1448565B1 (en) | 2001-11-30 | 2009-12-30 | Schering Corporation | ADENOSINE A2a RECEPTOR ANTAGONISTS |
PT2206517T (pt) | 2002-07-03 | 2023-11-07 | Tasuku Honjo | Composições de imunopotenciação contendo anticorpos anti-pd-l1 |
AU2003272886A1 (en) | 2002-09-24 | 2004-04-19 | Kyowa Hakko Kogyo Co., Ltd. | (1,2,4)-TRIAZOLO(1,5-c)PYRIMIDINE DERIVATIVE |
ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
EP1591527B1 (en) | 2003-01-23 | 2015-08-26 | Ono Pharmaceutical Co., Ltd. | Substance specific to human pd-1 |
US7674791B2 (en) | 2003-04-09 | 2010-03-09 | Biogen Idec Ma Inc. | Triazolopyrazines and methods of making and using the same |
PT1678182E (pt) | 2003-10-28 | 2007-04-30 | Schering Corp | Processo para preparar 5-amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pirimidinas |
NZ550591A (en) | 2004-04-21 | 2010-10-29 | Schering Corp | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2A receptor antagonists |
US7472383B2 (en) | 2004-08-13 | 2008-12-30 | Sun Microsystems, Inc. | System and method for providing exceptional flow control in protected code through memory layers |
CA2591125A1 (en) | 2004-12-21 | 2006-06-29 | Schering Corporation | Pyrazolo[1,5-a]pyrimidine adenosine a2a receptor antagonists |
ES2427646T5 (es) | 2005-05-09 | 2017-08-22 | Ono Pharmaceutical Co., Ltd. | Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos |
MX2007015942A (es) | 2005-07-01 | 2008-03-07 | Medarex Inc | Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada. |
CN101312978A (zh) | 2005-09-19 | 2008-11-26 | 先灵公司 | 作为腺苷A2a受体拮抗剂的2-杂芳基-吡唑并-[4,3-e]-1,2,4-三唑并-[1,5-c]-嘧啶 |
DE602007004851D1 (de) | 2006-06-26 | 2010-04-01 | Schering Corp | A2a-adenosin-rezeptor-antagonisten |
RS53072B (en) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | HUMAN RECEPTOR ANTIBODIES PROGRAMMED DEATH PD-1 |
PE20091101A1 (es) | 2007-12-18 | 2009-07-26 | Pharminox Ltd | AMIDAS DE ACIDO 3-SUBSTITUIDO-4-OXO-3,4-DIHIDRO-IMIDAZO[5,1-d] [1,2,3,5-TETRACINA-8-CARBOXILICO Y SU EMPLEO |
AU2009222040A1 (en) | 2008-03-04 | 2009-09-11 | Schering Corporation | Amino-quinoxaline and amino-quinoline compounds for use as adenosine A2a receptor antagonists |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
EP2328919A2 (en) | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
PL2342226T3 (pl) | 2008-09-26 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania |
HUE034832T2 (hu) | 2008-12-09 | 2021-12-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására |
EP2509983B1 (en) | 2009-11-16 | 2014-09-17 | Merck Sharp & Dohme Corp. | FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
CN103842030B (zh) | 2011-08-01 | 2018-07-31 | 霍夫曼-拉罗奇有限公司 | 使用pd-1轴结合拮抗剂和mek抑制剂治疗癌症的方法 |
US9495379B2 (en) | 2012-10-08 | 2016-11-15 | Veritas Technologies Llc | Locality aware, two-level fingerprint caching |
WO2014101113A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
WO2014101120A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
WO2015027431A1 (en) | 2013-08-29 | 2015-03-05 | Merck Sharp & Dohme Corp. | 2,2-difluorodioxolo a2a receptor antagonists |
JP6779204B2 (ja) | 2014-11-18 | 2020-11-04 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | A2a拮抗薬特性を有するアミノピラジン化合物 |
US10085991B2 (en) | 2014-12-04 | 2018-10-02 | Merck Sharp & Dohme Corp. | Formulation inhibiting effects of low acid environment |
US10138212B2 (en) | 2015-02-06 | 2018-11-27 | Merck Sharp & Dohme Corp. | Aminoquinazoline compounds as A2A antagonist |
EP3307067B1 (en) | 2015-06-11 | 2022-11-02 | Merck Sharp & Dohme LLC | Aminopyrazine compounds with a2a antagonist properties |
EP3313187B1 (en) | 2015-06-26 | 2020-08-05 | Merck Sharp & Dohme Corp. | Sustained release formulation and tablets prepared therefrom |
WO2017008205A1 (en) | 2015-07-10 | 2017-01-19 | Merck Sharp & Dohme Corp. | Substituted aminoquinazoline compounds as a2a antagonist |
CN116768859A (zh) | 2017-01-20 | 2023-09-19 | 艾库斯生物科学有限公司 | 用于治疗癌症相关疾病的唑嘧啶 |
EP3723754A4 (en) | 2017-12-13 | 2021-05-19 | Merck Sharp & Dohme Corp. | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES |
CA3100731A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
WO2020106560A1 (en) | 2018-11-20 | 2020-05-28 | Merck Sharp & Dohme Corp. | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
MA55142A (fr) | 2018-11-20 | 2022-02-23 | Merck Sharp & Dohme | Amino-triazolopyrimidine et amino-triazolopyrazine substitués antagoniste du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation |
MX2021006012A (es) | 2018-11-30 | 2021-07-06 | Merck Sharp & Dohme | Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso. |
-
2019
- 2019-11-26 EA EA202191498A patent/EA202191498A1/ru unknown
- 2019-11-26 EP EP19827893.9A patent/EP3886988A1/en active Pending
- 2019-11-26 JO JOP/2021/0116A patent/JOP20210116A1/ar unknown
- 2019-11-26 AR ARP190103450A patent/AR117164A1/es unknown
- 2019-11-26 US US16/695,367 patent/US11312719B2/en active Active
- 2019-11-26 AU AU2019385905A patent/AU2019385905B2/en active Active
- 2019-11-26 MX MX2021006329A patent/MX2021006329A/es unknown
- 2019-11-26 PE PE2021000757A patent/PE20211768A1/es unknown
- 2019-11-26 CN CN201980090487.8A patent/CN113329791A/zh active Pending
- 2019-11-26 KR KR1020217019802A patent/KR102653800B1/ko active IP Right Grant
- 2019-11-26 CR CR20210271A patent/CR20210271A/es unknown
- 2019-11-26 JP JP2021530114A patent/JP7241871B2/ja active Active
- 2019-11-26 WO PCT/US2019/063136 patent/WO2020112700A1/en active Application Filing
- 2019-11-26 JO JOP/2021/0117A patent/JOP20210117A1/ar unknown
- 2019-11-26 SG SG11202105180PA patent/SG11202105180PA/en unknown
- 2019-11-26 TW TW108142874A patent/TW202039496A/zh unknown
- 2019-11-26 MA MA054298A patent/MA54298A/fr unknown
- 2019-11-26 CA CA3120862A patent/CA3120862C/en active Active
- 2019-11-26 BR BR112021010427-5A patent/BR112021010427B1/pt active IP Right Grant
-
2021
- 2021-05-20 IL IL283334A patent/IL283334A/en unknown
- 2021-05-24 NI NI202100043A patent/NI202100043A/es unknown
- 2021-05-25 PH PH12021551196A patent/PH12021551196A1/en unknown
- 2021-05-25 EC ECSENADI202136982A patent/ECSP21036982A/es unknown
- 2021-05-26 CO CONC2021/0006888A patent/CO2021006888A2/es unknown
- 2021-05-27 CL CL2021001406A patent/CL2021001406A1/es unknown
- 2021-05-27 DO DO2021000104A patent/DOP2021000104A/es unknown
-
2022
- 2022-03-31 US US17/657,515 patent/US20220220117A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2021006329A (es) | 2021-08-11 |
AU2019385905B2 (en) | 2023-01-12 |
BR112021010427A2 (pt) | 2021-08-17 |
US20220220117A1 (en) | 2022-07-14 |
JOP20210116A1 (ar) | 2023-01-30 |
PH12021551196A1 (en) | 2021-11-29 |
CA3120862A1 (en) | 2020-06-04 |
JP2022511441A (ja) | 2022-01-31 |
DOP2021000104A (es) | 2021-07-30 |
EP3886988A1 (en) | 2021-10-06 |
MA54298A (fr) | 2022-03-09 |
CN113329791A (zh) | 2021-08-31 |
US20210107904A1 (en) | 2021-04-15 |
US11312719B2 (en) | 2022-04-26 |
BR112021010427B1 (pt) | 2022-09-27 |
JOP20210117A1 (ar) | 2023-01-30 |
EA202191498A1 (ru) | 2021-08-20 |
CL2021001406A1 (es) | 2021-11-12 |
JP7241871B2 (ja) | 2023-03-17 |
CA3120862C (en) | 2024-05-07 |
AU2019385905A1 (en) | 2021-06-03 |
KR102653800B1 (ko) | 2024-04-01 |
IL283334A (en) | 2021-07-29 |
TW202039496A (zh) | 2020-11-01 |
NI202100043A (es) | 2021-08-13 |
KR20210096184A (ko) | 2021-08-04 |
SG11202105180PA (en) | 2021-06-29 |
CO2021006888A2 (es) | 2021-06-10 |
CR20210271A (es) | 2021-07-14 |
PE20211768A1 (es) | 2021-09-07 |
WO2020112700A1 (en) | 2020-06-04 |
ECSP21036982A (es) | 2021-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR117164A1 (es) | Derivados de amino-triazoloquinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso para el tratamiento de diversos tipos de cáncer | |
US7332502B2 (en) | Phenanthroindolizidine alkaloids | |
KR102246652B1 (ko) | 암 치료용 화합물 | |
EP3411035B1 (en) | Aminothiazole compounds and use thereof | |
CA2754808C (en) | Prodrug forms of kinase inhibitors and their use in therapy | |
AR115985A1 (es) | Compuestos de pirazina y usos de los mismos | |
CO2022001357A2 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
CO2018004800A2 (es) | Antagonistas del receptor muscarinico 4 y metodos de uso. | |
AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
AR035774A1 (es) | Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento | |
AR053364A1 (es) | Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis | |
AR107714A1 (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
ECSP056115A (es) | ANTAGONISTAS DEL RECEPTOR A2a DE 2-ALQUINIL- Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA ADENOSINA | |
PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
JP2011512395A (ja) | 組合せ療法238 | |
CR20180172A (es) | Derivados de 8-[6-[3-(amino) propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer | |
KR101686679B1 (ko) | 퀴나졸린 유도체 | |
AR038401A1 (es) | Derivados de indazol substituidos como agentes terapeuticos | |
AR105975A1 (es) | Sulfonamidas tricílicas limitadas heterocíclicas como agentes contra el cáncer | |
BRPI0707580A2 (pt) | combinaÇÕes compreendendo um inibidor cdk e um anticorpo do fator de crescimento ou antimitàtico | |
CL2022002772A1 (es) | Macrocíclicos de diaminas para tratamiento de cánceres y combinación con antagonistas del receptor de adenosina | |
JP2015500884A5 (es) | ||
AR091520A1 (es) | Inhibidores piranopiridona de tanquirasa | |
US9056111B1 (en) | Selective efflux inhibitors and related pharmaceutical compositions and methods of treatment | |
RU2018135141A (ru) | Низкомолекулярные индукторы активных форм кислорода и ингибиторы митохондриальной активности |